Publication Type : Journal Article
Publisher : National Journal of Physiology, Pharmacy and Pharmacology
Source : National Journal of Physiology, Pharmacy and Pharmacology, 2018; 8(1): 144-145, DOI: 10.5455/njppp.2018.8.0725025072017
Url : https://www.njppp.com/?mno=272281
Keywords : Hepatocellular carcinoma; Sorafenib; Barcelona Clinic Liver Cancer Staging; Transarterial Chemoembolization
Campus : Kochi
School : School of Medicine
Department : Gastroenterology
Year : 2018
Abstract : Sorafenib is an oral multikinase inhibitor used as a palliative intent for advanced hepatocellular carcinoma (HCC). Dermatologic toxicity is the main adverse effect limiting its use in many patients. However, Grade III dermatologic toxicity is rarely seen with low-dose sorafenib administration. Here, we discuss the case of a 72-year-old male patient who was treated with sorafenib 400 mg for HCC. After 18 days of administration, the patient complained of intense pain with blisters and ulcerations. The drug was discontinued, and topical corticosteroids and analgesics were given for the management. Review of the patients medication did not reveal the presence of any other possible drugs capable of producing dermatological toxicity.
Cite this Research Publication : Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N., "Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation", National Journal of Physiology, Pharmacy and Pharmacology, 2018; 8(1): 144-145, DOI: 10.5455/njppp.2018.8.0725025072017